As Crestor Patent Trial Nears, Generic Firms Seek To Block AstraZeneca Subsidiary From Suit
This article was originally published in The Pink Sheet Daily
Defendants in infringement case claim AstraZeneca Pharmaceuticals LP has no rights to the patent at issue.
You may also be interested in...
AstraZeneca mulls an appeal of an Australian Federal Court judge’s ruling on Crestor patents as the anti-cholesterol drug faces a patent cliff worldwide.
Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)
TOKYO - Offering a mixed bag of earnings results, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe all await action of some sort by subsidiaries to determine their FY2010 outcomes. For Shionogi, that means a need for a U.S. rebound from its Sciele subsdiary, Daiichi Sankyo is holding out for the results of Ranbaxy, and Mitsubishi Tanabe is eyeing the impact of its subsidiary-induced sales suspension. [Editor's note: Part 1 of the Japanese earnings roundup with Astellas and Eisai appeared yesterday (PharmAsia New, Aug. 3, 2010).]
Switching statins OTC will require comprehensive consumer education to enable self-selection and flexibility from FDA on the types of information it considers product labeling